Looking to offset declining margins, generic drug suppliers are diversifying capabilities and emphasizing specialty products, biosimilars and patient services.
Cigna said it “remains committed to its established M&A criteria and would only consider acquisitions that are strategically aligned, financially attractive, and have a high probability to close,” per a WSJ report.